8-K filing — Coherus Oncology, Inc. (CHRS)
Filed: 2026-08-28 AccNo: 0001104659-26-103316 Size: 625 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Coherus Announces Clinical Collaboration And Supply Agreement With Zumutor To Conduct Phase 1 Trial Of ZM008, NK Checkpoint Anti-LLT1 Monoclonal Antibody In Combination With LOQTORZI
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Coherus Oncology Files Prospectus For Offering $50M Common Shares
SEC.
Coherus Oncology shares are trading higher after the company announced a special dividend of contingent value rights.
Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the